Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978669 | 0.88 | MCL1 (0.44) | MCL1PTGER4 | |
| SCHEMBL3974743 | 0.86 | GUSB (0.39) | MCL1HTTERN1 | |
| SCHEMBL3975723 | 0.86 | GAA (0.38) | PTGER4HTT | |
| SCHEMBL3975349 | 0.86 | MCL1 (0.40) | MCL1PTGER1SGMS2HTT | |
| SCHEMBL3979525 | 0.78 | MCL1 (0.40) | MCL1 | |
| SCHEMBL3974737 | 0.78 | ALDH1A1 (0.35) | MCL1SGMS2 | |
| SCHEMBL3977732 | 0.77 | GUSB (0.39) | HTT | |
| SCHEMBL3977882 | 0.77 | GUSB (0.39) | HTTERN1 | |
| SCHEMBL4252122 | 0.77 | MCL1 (0.51) | MCL1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL3977768 | 0.75 | ADCYAP1R1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | MCL1 2480/4885PTGER1 561/4885PTGER4 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.